Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant WIDER: ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer
CTR20251325Phase 3Active
- Sponsor
- Novartis
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ribociclib in breast cancer, sponsored by Novartis. Started Sep 2025; status: active.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20251325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251325.